Literature DB >> 15207789

Adult Still's disease reflects a Th2 rather than a Th1 cytokine profile.

Osamu Saiki1, Hiroshi Uda, Norihiko Nishimoto, Takashi Miwa, Toru Mima, Tomoharu Ogawara, Naoto Azuma, Yoshinori Katada, Junko Sawaki, Hiroko Tsutsui, Kiyoshi Matsui, Akira Maeda, Kenji Nakanishi.   

Abstract

Adult Still's disease (ASD) is a chronic multisystemic disease. Extraordinarily high serum levels of IL-18 in ASD patients have been described, whereas the mechanism remains to be clarified. This study aimed to evaluate proinflammatory cytokines and to consider their pathological roles. In patients with rheumatic diseases (n = 151), blood samples were taken at the active phase and the serum levels of IL-18 and other proinflammatory cytokines were measured by ELISA. The extra-high levels of IL-18 were confirmed selectively in ASD patients (n = 10). In the active phase of ASD patients, the levels of IL-6 were elevated accordingly, but IL-1beta and TNF-alpha were undetectable. As to Th1-Th2 cytokines, the levels of IL-4 and IL-13, but not INF-gamma, IL-12, or IL-2, were elevated in all ASD patients examined. Moreover, the serum levels of IL-18 showed a good correlation with those of IL-4, suggesting that ASD reflects a Th2 rather than a Th1 cytokine profile.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15207789     DOI: 10.1016/j.clim.2004.03.023

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  9 in total

Review 1.  Adult-onset Still's disease with macrophage activation syndrome diagnosed and treated based on cytokine profiling: a case-based review.

Authors:  Ken Goda; Tsuneaki Kenzaka; Masahiko Hoshijima; Akihiro Yachie; Hozuka Akita
Journal:  Rheumatol Int       Date:  2019-09-20       Impact factor: 2.631

2.  Etanercept-refractory adult-onset Still's disease with thrombotic thrombocytopenic purpura successfully treated with tocilizumab.

Authors:  Keiichi Sumida; Yoshifumi Ubara; Junichi Hoshino; Tatsuya Suwabe; Rikako Hiramatsu; Eiko Hasegawa; Noriko Hayami; Masayuki Yamanouchi; Naoki Sawa; Fumi Takemoto; Kenmei Takaichi
Journal:  Clin Rheumatol       Date:  2010-03-12       Impact factor: 2.980

3.  [Adult-onset Still's disease, Schnitzler syndrome, and autoinflammatory syndromes in adulthood].

Authors:  P Lamprecht
Journal:  Z Rheumatol       Date:  2009-11       Impact factor: 1.372

4.  IL-13 Signaling in Liver Fibrogenesis.

Authors:  Yan Liu; Stefan Munker; Roman Müllenbach; Hong-Lei Weng
Journal:  Front Immunol       Date:  2012-05-11       Impact factor: 7.561

5.  Adult-onset Still's disease biological treatment strategy may depend on the phenotypic dichotomy.

Authors:  François Vercruysse; Thomas Barnetche; Estibaliz Lazaro; Emilie Shipley; François Lifermann; Alexandre Balageas; Xavier Delbrel; Bruno Fautrel; Christophe Richez; Thierry Schaeverbeke; Marie-Elise Truchetet
Journal:  Arthritis Res Ther       Date:  2019-02-12       Impact factor: 5.156

Review 6.  Adult-onset Still's disease: A disease at the crossroad of innate immunity and autoimmunity.

Authors:  Shijia Rao; Lemuel Shui-Lun Tsang; Ming Zhao; Wei Shi; Qianjin Lu
Journal:  Front Med (Lausanne)       Date:  2022-08-22

7.  Circulating regulatory T cells in adult-onset Still's disease: Focusing on their plasticity and stability.

Authors:  Yasuhiro Shimojima; Takanori Ichikawa; Dai Kishida; Ryota Takamatsu; Yoshiki Sekijima
Journal:  Clin Exp Immunol       Date:  2021-08-12       Impact factor: 4.330

Review 8.  Tocilizumab in the treatment of the adult-onset Still's disease: current clinical evidence.

Authors:  Hubert de Boysson; Jérome Février; Amélie Nicolle; Christophe Auzary; Loïk Geffray
Journal:  Clin Rheumatol       Date:  2012-10-30       Impact factor: 3.650

9.  Usefulness of Interleukin-18 as a Diagnostic Biomarker to Differentiate Adult-Onset Still's Disease With/Without Macrophage Activation Syndrome From Other Secondary Hemophagocytic Lymphohistiocytosis in Adults.

Authors:  Toshihiko Shiga; Yuji Nozaki; Daisuke Tomita; Kazuya Kishimoto; Yasuaki Hirooka; Koji Kinoshita; Masanori Funauchi; Itaru Matsumura
Journal:  Front Immunol       Date:  2021-10-08       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.